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SUMMARY – The aim was to determine immunohistochemical expression of NEDD9 protein 
in head and neck squamous cell carcinoma (HNSCC) and the possible relation of its expression with 
primary tumor size (T), regional lymph node status (N), stage of disease (TNM) and survival period. 
A total of 131 patients with primary tumor localization in the area of oropharynx, hypopharynx and 
larynx, monitored for at least 5 years after initial surgical treatment were analyzed. The study included 
128 male and three female patients, median age 62.0 (range 53.0-68.0) years. Of these, 105 (95%) 
patients showed positive NEDD9 expressed by dyed cytoplasm. There were no significant differences 
in NEDD9 expression according to TNM tumor status. Patients with positive NEDD9 expression 
had a significantly higher median (IQR) survival time 51.0 (15.0-60.0) months as compared to 22.5 
(9.0-55.0) months in patients with negative NEDD9 expression (p=0.048). NEDD9 negative expres-
sion, controlled for the influence of other variables included in the Cox’s proportional hazards model, 
had a significant hazard ratio (HR) of 2.10 (95% CI: 1.23-3.58; p=0.006). The results of our study 
showed that NEDD9 expression might be an independent prognostic marker in patients with 
 HNSCC regarding data on overall survival and mortality.
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Introduction
Head and neck squamous cell carcinoma (HN-
SCC) is the fifth most common cancer in humans in 
the world and the most common type of tumor of the 
upper respiratory and digestive mucosa1. This type of 
cancer is developing due to cumulative genetic chang-
es caused by tobacco and alcoholic carcinogenic 
agents2,3 , and viruses (e.g., human papillomavirus)3-5, 
together with genetic predisposition6,7. Improved sur-
gical and new radiotherapy techniques, and the intro-
duction of new chemotherapy drugs into multimodal 
treatment protocols failed to bring satisfactory increase 
in survival rates over the last few decades8. Unsatisfac-
tory progress in the survival of patients with head and 
neck cancer increases the need for further genetic and 
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molecular investigations to explain the onset and bio-
logical behavior of this type of cancer. Researchers 
have recently been focused on the new therapeutic 
modalities, but new biological prognostic tumor mark-
ers in patients with HNSCC were also extensively in-
vestigated9-12.
Neural precursor cell expressed, developmentally 
downregulated 9 protein (NEDD9) is included in the 
CAS protein group that is a component of normal and 
pathologically changed cells, and is associated with 
poor prognosis and more frequent metastases, as well 
as resistance to chemotherapy in various types of can-
cer13.
In recently published studies, NEDD9 showed al-
tered, typically elevated expression in different malig-
nant diseases such as breast cancer, renal cell carcino-
ma, hepatocellular carcinoma, lung cancer, gastric can-
cer, colorectal carcinoma, melanoma and glioblastoma.
Overexpression of NEED9 has been so far associ-
ated with a more invasive behavior, metastases, poorer 
disease-free and overall survival of patients, more ad-
vanced TNM staging, advanced differentiation grade 
and tumor size, with deep invasion and presence of 
vessel invasion14-25.
The goal of this investigation was to determine im-
munohistochemical expression of NEDD9 protein in 
HNSCC and find the possible correlation of its ex-
pression with the size of primary tumor (T), regional 
lymph node status (N), disease stage (TNM), survival 
period and mortality.
Patients and Methods
In this retrospective study, immunohistochemical 
expression of NEDD9 protein in HNSCC patients 
treated at the Division of Head and Neck Surgery, De-
partment of Surgical Oncology, University Hospital 
for Tumors, Sestre milosrdnice University Hospital 
Centre, Zagreb, Croatia, was evaluated in the 2000-
2006 period. The archived histopathologic material 
was used upon approval by the Ethics Committee of 
the Sestre milosrdnice University Hospital Centre. A 
total of 131 patients with primary tumor localization 
in the area of oropharynx, hypopharynx and larynx, 
monitored for at least 5 years after initial surgical 
treatment were analyzed (Table 1).
The following criteria were set for inclusion in the 
study: histopathologic diagnosis of HNSCC, radical 





n (%) 26 (19.8)
Positive expression:  
n (%) 105 (80.2)
Tumor site Larynx: n (%) 62 (47.3)
Hypopharynx or 
oropharynx: n (%) 69 (52.7)
T grade 1: n (%) 24 (18.3)
2: n (%) 57 (43.5)
3: n (%) 36 (27.5)
4: n (%) 14 (10.7)
T grade 
(groups)
Initial (T1-T2): n (%) 81 (61.8)
Advanced (T3-T4):  
n (%) 50 (38.2)
N grade 0: n (%) 61 (46.6)
1: n (%) 13 (9.9)
2: n (%) 49 (37.4)
3: n (%) 8 (6.1)
N grade 
(groups)
N0: n (%) 61 (46.6)
N1, 2 or 3: n (%) 70 (53.4)
M grade 
(groups)
M0: n (%) 131 (100.0)
M1: n (%) 0 (0.0)
Stage of disease 
(TNM)
1: n (%) 20 (15.3)
2: n (%) 20 (15.3)
3: n (%) 25 (19.1)
4: n (%) 66 (50.4)
Stage of disease  
(TNM)
(groups)
Initial (1-2): n (%) 40 (30.5)
Advanced (3-4): n (%) 91 (69.5)
Radiotherapy Without: n (%) 32 (24.4)
Postop: n (%) 99 (75.6)
Chemotherapy No: n (%) 119 (90.8)
Yes: n (%) 12 (9.2)
Death outcome No: n (%) 57 (43.5)
Yes: n (%) 74 (56.5)
Death causes Local relapse: n (%) 21/74 (28.4)
Dissemination:  
n (%) 13/74 (17.6)
Other causes 
indirectly related to 
primary disease: n (%)
40/74 (54.0)
Age (years): median (IQR) 62.0 (53.0-68.0)
BMI (kg/m2): median (IQR) 23.9 (20.9-27.7)
Survival time (months): median (IQR) 44.0 (12.0-60.0)
BMI = body mass index; IQR = interquartile range
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surgery as the first modality of treatment without in-
traoperative data on macroscopic presence of residual 
tumor, available TNM classification at the time of di-
agnosis, data on the treatment and course of the dis-
ease, information on patient survival and death from 
the disease history, and data from the Cancer Registry 
of the Croatian Public Health Institute. The study was 
performed on HNSCC tissue samples embedded in 
paraffin blocks at the Clinical Unit for Oncologic Pa-
thology, University Hospital for Tumors. Tissue sam-
ples were processed by the standard histologic proce-
dure that included 24-48 hour tissue fixation in 10% 
buffered formalin. After fixing in formalin, the process 
of tissue preparation through the upward series of al-
cohol and xylene, tissue was paraffin embedded. After 
the diagnosis was verified, the degree of tumor differ-
entiation was established and the histopathologic 
samples and paraffin blocks were archived. One addi-
tional cut of each primary tumor, 2-3 microns thick, 
was mounted on silanized glass, immunohistochemi-
cally dyed with primary mouse anti-human antibody 
to NEDD9 (clone 2G9, AbCam, USA), and diluted at 
1:50 ratio with the dilution buffer (Antibody Diluent, 
S2023, Dako, Denmark). Before starting the proce-
dure, the samples were dried in a thermostat at 60 oC 
for approximately 40 minutes, deparaffinized and re-
hydrated for antigen detection. All procedures were 
carried out simultaneously by cooking the Tris/EDTA 
buffer pH 9 at 97 °C for 20 minutes in a PT link de-
vice (Dako, Denmark). Immunohistochemical stain-
ing was performed by automatic processing in a Dako 
Autostainer Universal Staining System by the strepta-
vidin immunoperoxidase method.
All immunohistochemical staining reagents were 
included in the visualization kit EnVision Flex High 
pH (K8010, Dako, Denmark). Visualization of the 
specific reaction was made with DAB (diaminobenzi-
dine) chromogenic and contrasting coloration with 
hematoxylin-eosin.
According to the manufacturer’s instructions, a 
positive immunohistochemical reaction is considered 
if the cytoplasm is dyed. The percentage of cancer cells 
stained in high-power fields was estimated by semi-
quantitative method.
The percentage of positive tumor cells was graded 
as 0 (negative reaction); + (weak reaction; 1): more 
than 10% of positive tumor cells; ++ (moderate reac-
tion; 2): 11%-50% of positive tumor cells; and +++ 
(strong reaction; 3): more than 51% of positive tumor 
cells.
The intensity of staining was recorded as weak (1), 
moderate (2) and strong (3).
As a result, these two scores (percentage of positive 
tumor cells and intensity of staining) were multiplied 
and the immunoreactive score (IRS) was determined 
as negative (0;1;2;3) and positive (4;6;9).
Statistical methods
Data are presented in tables and figures. After test-
ing for normality by Kolmogorov-Smirnov test, it was 
decided to use non-parametric tests in the analyses. 
Categorical variables were presented as frequency and 
corresponding percentage, and quantitative variables 
as median and interquartile range (25th to 75th percen-
tile). Fisher-Freeman-Halton exact test of indepen-
dence when the contingency table is larger than 2x2 
was used to analyze differences in categorical clinical 
parameters between NEDD9 expression grades. 
Mann-Whitney U test was used to analyze differences 
in survival time between the same groups. Kaplan-
Meier survival analysis with Log-Rank (Mantel-Cox) 
test was used to analyze survival according to NEDD9 
expression for 60-month follow-up. In addition, Cox’s 
proportional hazards model for survival-time model 
was made to assess multivariate predictive model for 
time-to-death event data. All p values below 0.05 were 
considered significant. The IBM SPSS Statistics, ver-
sion 25.0 data analysis software (https://www.ibm.
com/analytics/spss-statistics-software) was used on 
statistical analyses and graphic images.
Results
The study included 128 male and three female pa-
tients, median age 62.0 (range 53.0-68.0) years. Of 
these, 105 (95%) patients showed positive NEDD9 ex-
pressed by dyed cytoplasm. Differences in NEDD9 ex-
pression according to the size of primary tumor (T), 
regional lymph node status (N status), stage of the dis-
ease (TNM) and survival period in months are present-
ed in Table 2. There were significant differences in sur-
vival outcome according to NEDD9 expression, i.e. 
patients with positive NEDD9 expression had a signifi-
cantly lower mortality rate compared to patients with 
negative NEDD9 expression: 54 (54.4%) vs. 20 (76.9%) 
(p=0.026). Also, patients with positive NEDD9 expres-
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Table 2. Differences in NEDD9 expression in relation to the size of primary tumor (T), regional lymph node status  
(N status), stage of the disease (TNM) and survival period in months (Fisher-Freeman-Halton exact test)
NEDD expression grade 
pNegative expression Positive expressionn=26 n=105
n (%) n (%)
T grade 1 7 (26.9) 17 (16.2)
0.5542 9 (34.6) 48 (45.7)3 7 (26.9) 29 (27.6)
4 3 (11.5) 11 (10.5)
T grade (groups) Initial (T1-T2) 16 (61.5) 65 (61.9) 1.000Advanced (T3-T4) 10 (38.5) 40 (38.1)
Stage of disease (TNM) 1 6 (23.1) 14 (13.3)
0.6022 4 (15.4) 16 (15.2)3 5 (19.2) 20 (19.0)
4 11 (42.3) 55 (52.4)
Stage of disease (TNM); 
(groups)
Initial (1-2) 10 (38.5) 30 (28.6) 0.348Advanced (3-4) 16 (61.5) 75 (71.4)
N grade 0 13 (50.0) 48 (45.7)
0.8181 3 (11.5) 10 (9.5)2 8 (30.8) 41 (39.0)
3 2 (7.7) 6 (5.7)
N grade (groups) Negative (N0) 13 (50.0) 48 (45.7) 0.827Positive (N 1, 2 or 3) 13 (50.0) 57 (54.3)
Tumor site Larynx 12 (46.2) 50 (47.6) 1.000Hypopharynx or oropharynx 14 (53.8) 55 (52.4)
Death outcome No 6 (23.1) 51 (48.6) 0.026Yes 20 (76.9) 54 (54.4)
Cumulative survival time (months): median (IQR) 22.5 (9.0-55.0) 51.0 (15.0-60.0) 0.048
IQR = interquartile range analyzed with Mann-Whitney U test
sion had a significantly higher median (interquartile 
range, IQR) survival time: 51.0 (15.0-60.0) months 
compared to 22.5 (9.0-55.0) months in patients with 
negative NEDD9 expression (p=0.048).
Kaplan-Meier survival analysis and Log-Rank 
(Mantel-Cox) test also yielded significant difference 
in survival rate, indicating that patients with positive 
NEDD9 expression had better survival (p=0.020) 
(Fig. 1).
The Cox’s proportional hazards model produced a 
survival function that predicted the probability that 
the death event had occurred within 60-month fol-
low-up for the given values of predictor variables. Re-
gression model was statistically significant (χ2=38.04, 
df=8; p<0.001). NEDD9 negative expression, con-
trolled for the influence of other variables included in 
the model, had a significant hazard ratio (HR) of 2.10 
(95% confidence interval (CI): 1.23-3.58; p=0.006). 
This result indicated the significance of NEDD9 ex-
pression in survival rate in the multivariate survival 
model and negative NEDD9 expression should be 
considered as important survival predictor.
Discussion
The NEDD9 is labeled as a protein that increases 
the metastatic potential of melanoma14. Natarajan et al. 
found NEDD9 to have an important role in the inva-
sive behavior of glioblastoma cells15. Expression of the 
growth hormone receptor (GHR) and NEDD9 was 
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analyzed in breast cancer and association with tumor 
aggressiveness was found16,17. Furthermore, both pro-
teins showed increased expression in epithelial and 
stromal compartments of primary ductal invasive 
breast carcinomas and their axillary lymph node me-
tastases in comparison to non-metastatic tumors16. An 
important role in the carcinogenesis of renal cell carci-
noma (RCC) was demonstrated by low expression of 
NEDD9 in normal renal tissues and high expression 
in RCC tissues18. Patients with verified hepatocellular 
carcinoma (HCC) and high expression of NEDD9 
showed poorer recurrence-free interval and overall 
survival versus those with low expression of NEDD9. 
These results suggest that NEDD9 may be a prognos-
tic biomarker for HCC, including early-stage tumor 
and alfa-fetoprotein normal patients19. NEDD9 pro-
motes lung cancer metastasis20. Overexpression of 
NEDD9 in patients with lung adenocarcinoma has 
been strongly correlated with staging, grade and tumor 
size, demonstrating poor prognosis21. Patients with 
gastric carcinoma showed higher NEDD9 expression 
in advanced tumors (TNM stages III and IV), deep 
invasion (T3, T4), presence of vessel invasion, lymph 
node and distant metastases, indicating that NEDD9 
overexpression was involved in the progression of gas-
tric cancer22. Additionally, high expression of NEDD9 
was significantly associated with poor prognosis and 
the expression of NEDD9 was an independent prog-
nostic factor22. A study conducted by another group of 
Chinese investigators revealed that the more advanced 
clinical TNM stage of gastric carcinoma corresponded 
to higher expression level of NEDD923. According to 
their results, NEDD9 is a tumor-promoting factor and 
thus could be used as an independent biomarker for 
poor survival23. In colorectal cancer, NEDD9 plays an 
important role in tumor genesis and cancer progres-
sion. Furthermore, increased NEDD9 expression was 
significantly correlated with advanced TNM stage, pT 
grade, pN and pM status, and shorter overall survival24.
On the contrary, in pancreatic adenocarcinoma, 
NEDD9 did not show any statistical correlation with 
tumor stage and grade, gender or patient survival25. 
Polymerase chain reaction of nasopharyngeal carcino-
ma biopsy samples confirmed the significant decline in 
NEDD9 mRNA expression in cancer tissues com-
pared to the adjacent non-tumor tissue26.
To the best of our knowledge, this is the first study 
analyzing the grade of immunohistochemical staining 
of NEDD9 protein in HNSCC in relation to the size 
of tumor (T), clinical stage of disease (TNM) and pa-
tient survival. Immunohistochemical expression of 
NEDD9 was over 95%, showing variability in semi-
quantitative expression. The group with negative 
NEDD9 expression had a significantly higher mortal-
ity when compared to the group with positive NEDD9 
expression. As NEDD9 expression was not signifi-
cantly correlated with tumor size, N status and disease 
stage, these results imply that NEDD9 expression is a 
significant independent indicator of mortality. The 
mean survival of NEDD9 negative patients was sig-
nificantly lower when compared to NEDD9 positive 
patients. The results of our study support the assump-
tion that NEDD9 expression might be an indepen-
dent prognostic marker in patients with HNSCC con-
sidering data on survival time and mortality.
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Sažetak
POZITIVNA EKSPRESIJA NEDD9 U KARCINOMIMA GLAVE I VRATA  
POVEZANA JE S BOLJIM PREŽIVLJENJEM
I. Ledinsky Opačić, K. Gršić, S. Šitić, I. Penavić, M. Pastorčić Grgić i B. Šarčević
Cilj je bio utvrditi imunohistokemijsku ekspresiju proteina NEDD9 i moguću povezanost ekspresije s veličinom tumora 
(T), statusom regionalnih limfnih čvorova (N), kliničkim statusom bolesti (TNM) i preživljenjem bolesnika s planocelular-
nim karcinomom glave i vrata. Analiziran je 131 bolesnik s primarnim tumorom lokaliziranim u orofarinksu, hipofarinksu i 
larinksu, a bolesnici su praćeni najmanje pet godina nakon inicijalnog kirurškog liječenja. Studija je uključivala 128 muška-
raca i tri žene, medijan životne dobi od 62,0 (raspon 53,0-68,0) godine. Ukupno je 105 (95%) bolesnika imalo pozitivan 
NEDD9 vidljiv imunohistokemijskim bojanjem citoplazme. Nije nađeno značajne razlike u ekspresiji NEDD9 u odnosu na 
status TNM. Bolesnici s pozitivnom ekspresijom NEDD9 imali su značajno viši medijan (IQR) razdoblja preživljenja: 51,0 
(15,0-60,0) mjesec prema 22,5 (9,0-55,0) mjeseca kod bolesnika s negativnom ekspresijom NEDD9 (p=0,048). Negativna 
ekspresija NEDD9 pod kontrolom utjecaja drugih varijabla imala je značajan omjer rizika, uključujući Coxov proporcional-
ni model rizika (HR) od 2,10 (95% CI: 1,23-3,58; p=0,006). Rezultati naše studije su pokazali da ekspresija NEDD9 može 
biti nezavisan prognostički biljeg u bolesnika s karcinomom glave i vrata s obzirom na podatke o ukupnom preživljenju i 
smrtnosti.
Ključne riječi: Glava i vrat, tumori; Planocelularni karcinom glave i vrata; Imunohistokemija; Tumori, određivanje stadija; 
Preživljenje bez znakova bolesti; Smrtnost
